Uncategorized
TNF inhibitor effective in patients with severe uveitis
Adalimumab may treat patients with severe uveitis even if a systemic disease is present, according to a study.The retrospective study included 60 patients with uveitis; 41 patients had both uveitis and systemic disease. Patients underwent treatment with adalimumab with a mean follow-up of 87.9 weeks.